JNJ in 60 seconds
Two operating segments after the 2023 Kenvue spin: Innovative Medicine (drugs) and MedTech (devices). Annual revenue runs around $87 billion, with Innovative Medicine contributing roughly two thirds and MedTech the rest. Stelara peaked near $10 billion in annual sales; US biosimilar competition began in 2025 and the erosion curve is the most-discussed line in every earnings call. The dividend has been raised for 62 straight years and sits near $1.24 per share per quarter. At LHFX you trade JNJ as a CFD on MT5 with raw spreads, $3 commission per side, and a 1:20 leverage cap on US single-stock CFDs.
What the company actually does
Johnson & Johnson is a healthcare conglomerate built around two engines: a high-margin drug portfolio and a global medical-device franchise. The familiar consumer products (Tylenol, Band-Aid, Listerine, Neutrogena, the baby brand) were carved out in August 2023 as Kenvue and trade independently under KVUE. The parent company that remains is a pure pharma plus devices business and looks structurally different from the J&J an investor remembered ten years ago.
Innovative Medicine is the larger half. Inside that segment, four therapy areas carry the revenue. Immunology houses Stelara and the heir-apparent Tremfya. Oncology is anchored by Darzalex in multiple myeloma plus a wave of CAR-T and bispecific assets including Carvykti, Talvey, and Tecvayli. Neuroscience contains Spravato for treatment-resistant depression alongside the legacy Invega antipsychotic franchise. Infectious disease and vaccines round out the segment.
MedTech is the part of the business most retail investors underweight. It groups four platforms: orthopaedics through DePuy Synthes (hips, knees, spine, trauma), surgery (including the Abiomed cardiovascular acquisition closed in late 2022 for $16.6 billion), interventional solutions (electrophysiology and neurovascular), and vision (Acuvue contact lenses). The robotic-surgery effort runs across Monarch in bronchoscopy and the Ottava platform in general surgery, which is meant to challenge Intuitive Surgical's dominance in soft-tissue robotics.
How the business actually makes money
Two segments, very different cost structures. A trader needs to know which one is moving the print. Once you can place a result in the right segment you can read the print quickly. A weak quarter where MedTech grew double-digits but Innovative Medicine missed is a Stelara story. A weak MedTech print with a clean drug number is usually a hospital-utilisation story and reads across to Stryker, Medtronic, and Boston Scientific.
Innovative Medicine: around two thirds of revenue
High-margin patented drugs. Operating margins in the high 30s to low 40s. Revenue concentration in roughly ten brands. Watch Stelara unit volumes, Carvykti capacity ramp, Tremfya IBD launch trajectory, and oncology pipeline readouts at ASCO and ASH.
MedTech: around one third of revenue
Capital equipment plus consumables. Lower margins in the low 20s. Volume is procedure-driven and sensitive to hospital staffing. Watch Abiomed Impella growth, electrophysiology share against Boston Scientific, and Monarch and Ottava commercial milestones.
What moves JNJ between earnings
Five repeat drivers do most of the work outside the quarterly print.
Stelara unit and revenue trajectory
Stelara is roughly 12 to 14 percent of revenue and the biosimilar erosion curve is the single largest variable in consensus models. Each quarter the print is compared to a sell-side erosion curve; coming in lighter or steeper than that curve is the move. This is the heaviest weight in the 2025 to 2026 narrative.
Oncology pipeline data
Carvykti, Talvey, Tecvayli, and the broader bispecific pipeline read out at ASCO (early June) and ASH (early December). Strong data extends the revenue offset to Stelara loss of exclusivity; weak data forces a re-rate. Episodic but high amplitude.
MedTech share and operating margin
MedTech share trends in electrophysiology versus Boston Scientific and orthopaedics versus Stryker drive segment growth. Operating-margin recovery toward mid-20s is a multi-year strategic goal management restates on every call. Quietly important.
Talc litigation headlines
Cosmetic talc claims sit with J&J subsidiaries (notably LTL Management). Settlement-structure headlines, bankruptcy court rulings, and class-agreement news produce 2 to 5 percent single-day moves with no warning. Tail risk, high frequency.
Dollar index direction
Around half of revenue is non-US. A stronger dollar drags reported growth; a weaker dollar flatters it. Currency is called out as a separate line in operational versus reported growth on every quarter. Slow burn.
Earnings calendar and what to watch
JNJ reports four times a year, always pre-market US, and almost always before any other large-cap healthcare name. The release sets sector tone for the rest of the week. Q4 lands in mid-January with full-year guidance and Stelara erosion commentary. Q1 in mid-April carries the first full quarter of US Stelara biosimilar pressure plus currency headwind sizing. Q2 in mid-July brings the mid-year guidance update and Carvykti capacity status. Q3 in mid-October sets up the next-year outlook commentary that lands on the Q4 call.
Implied moves on earnings have run 2 to 4 percent in recent quarters. That is well below the S&P 500 single-stock average and reflects the defensive multiple. The non-earnings catalysts that produce comparable single-day moves are talc litigation headlines and major oncology readouts at ASCO (early June) and ASH (early December).
A trader carrying a leveraged JNJ position into one of those releases should expect overnight margin requirements to widen and slippage to be larger than on a quiet midweek session. Earnings days are the only routine setup with a structural overnight gap on JNJ. Hold size accordingly or close the position before the bell.
How a typical earnings day plays out on JNJ
JNJ at $158 going into the Q1 release. Consensus has Stelara revenue down a specific percentage versus prior-year. The release prints, Stelara comes in 200 basis points worse than that erosion curve, and the stock opens 2.8 percent lower at $153.58. A long 0.05-lot CFD position carried through the print at $158 with $7.90 of margin at 1:20 leverage loses $22.10 plus $6 round-trip commission, or roughly $28.10 in total. The position used $7.90 of margin, so the loss is 356 percent of margin. This is why earnings overnight exposure is sized differently from mid-week directional trades.
When JNJ actually trades
JNJ is a NYSE-listed name. The CFD on LHFX follows US cash hours. Earnings days are the only routine setup with a structural overnight gap. Hold size accordingly or close before the bell.
14:30 to 21:00 UTC, Monday to Friday. All sizing windows live here. The first 15 minutes after the open and the last 15 before the close run the widest spreads.
Not tradeable on the CFD. Earnings prints land in this window. Position takers gap on the open, which is why size into a release is a different decision from size during cash hours.
Closed on NYSE-published US holidays. Includes the half-day sessions around Thanksgiving Friday and Christmas Eve. Liquidity thins ahead of those half-days even before the early close, so spreads widen visibly.
Plan position closures the prior session rather than scrambling on a short-day open. Earnings overnight is the routine gap risk, half-day sessions are the routine liquidity risk.
CFD versus owning the underlying share
A CFD on JNJ is a contract that settles against the share price. Direct ownership of the JNJ common stock is a different product with different tax, voting, and settlement consequences. The table below is the practical comparison.
| Feature | JNJ CFD at LHFX | Direct JNJ share |
|---|---|---|
| Price exposure | Linear: $1 share move equals $1 PnL per CFD unit. | Linear: the same $1 move equals the same $1 PnL per share owned. |
| Leverage | Up to 1:20 at LHFX. | Typically cash or 2:1 in a US margin account. |
| Minimum size | Fractional position size on MT5. | Whole shares (some US brokers now offer fractionals). |
| Short selling | Open a sell CFD, no borrow required on your side. | Requires a share locate and a margin account. |
| Dividends | Cash adjustment on the ex-date, no franking or tax voucher. | Paid as a cash dividend with broker tax reporting. |
| Voting rights | None. | Proxy vote at the New Brunswick AGM. |
| Holding cost | Daily financing on the position size. | None on cash equity; margin interest if borrowed. |
| Hours | US cash session, 14:30 to 21:00 UTC. | US cash session plus pre-market and after-hours at most US brokers. |
| Counterparty | LHFX, settled in USD. | DTCC settlement, paper or book entry. |
Neither product is universally better. CFDs give you fractional sizing, two-sided positioning, and tighter capital use. Direct ownership gives you the share itself, the proxy, and tax treatment that does not include daily financing. Pick the product that matches the position you actually want to express.
Where JNJ sits versus its peers
Within healthcare, JNJ is the diversified anchor. Pfizer (PFE) is more exposed to a single product cycle at any given moment, currently the Covid franchise unwind and Seagen integration. Moderna (MRNA) is a pure-play mRNA story with revenue concentration and binary clinical events. Procter & Gamble (PG) and Coca-Cola (KO) sit in the same defensive bucket from a multiple-and-yield perspective but trade on entirely different end markets (household goods and beverages).
If the question is which healthcare CFD to express a defensive view through, JNJ is the most index-like option of the four healthcare comparables. PFE has bigger swings on franchise concerns. MRNA is high-beta. PG and KO are useful as defensive cross-checks rather than substitutes.
How JNJ behaves on an LHFX account
JNJ is available as a single-name CFD inside the LHFX MetaTrader 5 environment and on the LHFX Trade web platform. Pricing is raw STP/ECN, which means the quote you see is the same quote routed through to the venue with no internal dealing-desk markup. The cost of trading is a flat $3 per side, so $6 for a round-trip ticket, on top of the bid-ask printed at the moment of execution.
MetaTrader 5 desktop, the MT5 mobile app, or LHFX Trade in the browser. Search JNJ in Market Watch. Same chart, indicators, and order types as your forex or commodities positions.
STP/ECN execution. No dealing-desk routing on the path between your click and the venue. Limit orders during the opening minutes fill noticeably tighter than market orders because of opening-auction volatility.
$3 per side. A round trip on a single JNJ position is $6 of commission regardless of size. The structure is linear by lot size, which makes the all-in cost predictable when sizing a strategy across multiple symbols.
Maximum 1:20 on US single-stock CFDs. That is a ceiling, not a target. A 5 percent gap on a fully sized 1:20 position consumes 100 percent of posted margin, so effective leverage of 1:3 to 1:5 is the conservative range for most non-professional traders.
Raw spreads off the underlying NYSE quote during cash hours. Widest in the first 15 minutes after the open and the last 15 before the close. Mid-session is where most sizing should happen.
Monday to Friday, 14:30 to 21:00 UTC. NYSE regular cash session. Closed on US public holidays. The CFD does not trade in pre-market or post-market.
Sizing a JNJ position: worked example
Account balance $2,500. JNJ trading at $158. Plan is a 4 percent stop on the share price and a 1.5 percent loss budget on the account. Loss budget in dollars is 1.5 percent of $2,500, which is $37.50. Per-share stop distance is 4 percent of $158, which is $6.32 below entry. Position size is $37.50 divided by $6.32, which equals 5.9 shares. Round down to 5 shares, notional $790. Margin requirement at 1:20 is $790 divided by 20, which is $39.50 of equity tied up. Round-trip commission is $6, so the trade needs the share to move roughly $1.20 net to break even after fees. If the stop is hit, the loss is $6.32 multiplied by 5 shares, which is $31.60, plus $6 commission, totalling $37.60. That is inside the $37.50 budget by 10 cents. The mechanic is identical regardless of which numbers you plug in. Size the loss in dollars first, then derive the share count.
See live pricing and instrument specifications on the JNJ instrument page, review the full cost table on spreads and fees, and check the cap on the leverage page.
Risks specific to trading JNJ
Three failure modes show up most often on real positions. Each has a simple counter. Mitigation is straightforward in description and harder in practice. Use a working stop loss on every position, do not run unhedged exposure through earnings, and recompute notional and margin after every position addition.
Biosimilar surprise
Stelara erosion runs faster than the curve baked into consensus. A single weak quarter on Stelara unit volume can re-rate the Innovative Medicine multiple. Read the Stelara revenue line in the press release before reading anything else. Hold reduced size into Q1 and Q2 prints during the heaviest biosimilar transition window.
Litigation headline
Talc settlement news, bankruptcy court rulings, or class-action developments hit without scheduling. Single-day moves of 2 to 5 percent are normal on these days. A working stop loss on every position. If you only check the platform once a day, set the stop tight enough to survive an unattended news day.
Leverage drift
1:20 is a cap, not a recommendation. Many traders open a small position then add into it without recalculating margin. A 5 percent adverse move on a fully sized 1:20 position consumes 100 percent of margin. Recompute notional and margin after every addition. If the answer is uncomfortable, the position is too big.
Risk warning. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.